Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results
10 mai 2017 16h02 HE
|
Anthera Pharmaceuticals, Inc.
RESULT, pivotal Phase 3 Study of Sollpura, is expected to screen the first patient in MayFavorable trends on weight, height, and body mass index (“BMI”) from the Extension Period of the SOLUTION Study...
Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
28 avr. 2017 16h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) announced today that it has filed a Certificate of Amendment to its Amended and Restated...
Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
10 avr. 2017 08h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2...
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
29 mars 2017 16h05 HE
|
Anthera Pharmaceuticals, Inc.
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 (GLOBE...
Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
14 mars 2017 08h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the “Company”) today announced the pricing of an underwritten public offering of 30,000,000...
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
13 mars 2017 16h01 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the “Company”) today announced that it intends to offer and sell shares of its common stock...
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results
27 févr. 2017 16h05 HE
|
Anthera Pharmaceuticals, Inc.
SOLUTION study with Sollpura™ missed non-inferiority endpoint by 1%, prompting new phase 3 studyData Monitoring Committee issued recommendation to continue SIMPLICITY study with Sollpura™Blisibimod...
Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results – Additional Study Needed
27 déc. 2016 16h05 HE
|
Anthera Pharmaceuticals, Inc.
Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority marginSollpura demonstrated non-inferiority in the per protocol CFA analysisSollpura...
Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura™ Following Positive DMC Review
13 déc. 2016 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of...
Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy
06 déc. 2016 16h10 HE
|
Anthera Pharmaceuticals, Inc.
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of DirectorsPaul F. Truex appointed as Executive Chairman of the BoardDr. Christopher Henney stepped down as Chairman...